167 related articles for article (PubMed ID: 24084763)
1. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
Wang J; Carvajal-Carmona LG; Chu JH; Zauber AG; ; Kubo M; Matsuda K; Dunlop M; Houlston RS; Sieber O; Lipton L; Gibbs P; Martin NG; Montgomery GW; Young J; Baird PN; Ratain MJ; Nakamura Y; Weiss ST; Tomlinson I; Bertagnolli MM
Clin Cancer Res; 2013 Dec; 19(23):6430-7. PubMed ID: 24084763
[TBL] [Abstract][Full Text] [Related]
2. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial.
Barry EL; Peacock JL; Rees JR; Bostick RM; Robertson DJ; Bresalier RS; Baron JA
JAMA Oncol; 2017 May; 3(5):628-635. PubMed ID: 27978548
[TBL] [Abstract][Full Text] [Related]
4. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.
Bertagnolli MM; Hsu M; Hawk ET; Eagle CJ; Zauber AG;
Cancer Prev Res (Phila); 2010 May; 3(5):588-96. PubMed ID: 20403998
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Chan AT; Zauber AG; Hsu M; Breazna A; Hunter DJ; Rosenstein RB; Eagle CJ; Hawk ET; Bertagnolli MM
Gastroenterology; 2009 Jun; 136(7):2127-2136.e1. PubMed ID: 19233181
[TBL] [Abstract][Full Text] [Related]
6. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
7. Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP.
Cheng TH; Gorman M; Martin L; Barclay E; Casey G; ; ; Saunders B; Thomas H; Clark S; Tomlinson I
Eur J Hum Genet; 2015 Feb; 23(2):260-3. PubMed ID: 24801760
[TBL] [Abstract][Full Text] [Related]
8. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Breazna A; Kim K; Tang J; Rosenstein RB; Umar A; Bagheri D; Collins NT; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Hawk ET;
Cancer Prev Res (Phila); 2009 Apr; 2(4):310-21. PubMed ID: 19336730
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
11. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
12. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Thompson P; Roe DJ; Fales L; Buckmeier J; Wang F; Hamilton SR; Bhattacharyya A; Green S; Hsu CH; Chow HH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Martinez ME; Jacobs E; Ashbeck EL; Alberts DS; Lance P
Cancer Prev Res (Phila); 2012 Dec; 5(12):1381-93. PubMed ID: 23060037
[TBL] [Abstract][Full Text] [Related]
13. Presence of a TA haplotype in the APC gene containing the common 1822 polymorphism and colorectal adenoma.
Egan JB; Jacobs ET; Martínez ME; Gerner EW; Jurutka PW; Thompson PA
Cancer Res; 2008 Jul; 68(14):6006-13. PubMed ID: 18632657
[TBL] [Abstract][Full Text] [Related]
14. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Barry EL; Baron JA; Bhat S; Grau MV; Burke CA; Sandler RS; Ahnen DJ; Haile RW; O'Brien TG
J Natl Cancer Inst; 2006 Oct; 98(20):1494-500. PubMed ID: 17047198
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Barry EL; Sansbury LB; Grau MV; Ali IU; Tsang S; Munroe DJ; Ahnen DJ; Sandler RS; Saibil F; Gui J; Bresalier RS; McKeown-Eyssen GE; Burke C; Baron JA
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2726-33. PubMed ID: 19755647
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association study identifies possible genetic risk factors for colorectal adenomas.
Edwards TL; Shrubsole MJ; Cai Q; Li G; Dai Q; Rex DK; Ulbright TM; Fu Z; Delahanty RH; Murff HJ; Smalley W; Ness RM; Zheng W
Cancer Epidemiol Biomarkers Prev; 2013 Jul; 22(7):1219-26. PubMed ID: 23677573
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Chan AT; Sima CS; Zauber AG; Ridker PM; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1172-80. PubMed ID: 21816845
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.
Kleinstein SE; Heath L; Makar KW; Poole EM; Seufert BL; Slattery ML; Xiao L; Duggan DJ; Hsu L; Curtin K; Koepl L; Muehling J; Taverna D; Caan BJ; Carlson CS; Potter JD; Ulrich CM
Genes Chromosomes Cancer; 2013 May; 52(5):437-49. PubMed ID: 23404351
[TBL] [Abstract][Full Text] [Related]
19. Genetic Variants Associated with Colorectal Adenoma Susceptibility.
Abulí A; Castells A; Bujanda L; Lozano JJ; Bessa X; Hernández C; Álvarez-Urturi C; Pellisé M; Esteban-Jurado C; Hijona E; Burón A; Macià F; Grau J; Guayta R; Castellví-Bel S; Andreu M;
PLoS One; 2016; 11(4):e0153084. PubMed ID: 27078840
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers.
Ghorbanoghli Z; Nieuwenhuis MH; Houwing-Duistermaat JJ; Jagmohan-Changur S; Hes FJ; Tops CM; Wagner A; Aalfs CM; Verhoef S; Gómez García EB; Sijmons RH; Menko FH; Letteboer TG; Hoogerbrugge N; van Wezel T; Vasen HF; Wijnen JT
Fam Cancer; 2016 Oct; 15(4):563-70. PubMed ID: 26880076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
